Patients with CI-AKI had higher rates of net adverse clinical events [ NACE ; a combination of major bleeding or composite major adverse cardiac events ( MACE ; consisting of death , reinfarction , target vessel revascularization for ischaemia , or stroke ) ] at 30 days ( 22.0 vs. 9.3 % ; P < 0.0001 ) and 3 years ( 40.3 vs. 24.6 % ; P < 0.0001 ) .